GHK-Cu Hair and Skin Changes: What the Clinical Evidence Actually Shows

What GHK-Cu is

GHK-Cu is the copper(II) complex of GHK, a tripeptide (glycyl-L-histidyl-lysine) present in human plasma, saliva and urine, with levels reported to decline with age [5]. The actions usually attached to it come from laboratory and animal work summarized by the researchers who proposed its use: GHK is reported to stimulate collagen and proteoglycan synthesis, modulate metalloproteinases and their inhibitors, attract immune and endothelial cells to an injury, and speed wound healing in dogs, rats, mice and pigs [5]. Those are preclinical or proposed mechanisms, not measured human outcomes.

The clearest human-cell data come from a 2005 in vitro study. Pollard and colleagues cultured normal and irradiated human dermal fibroblasts with GHK-Cu at 1 x 10(-9) mol/L and found faster population doubling than untreated controls; treated irradiated cells doubled at roughly the rate of untreated normal cells, and irradiated cells produced significantly more basic fibroblast growth factor and vascular endothelial growth factor than untreated controls early after exposure [9]. That is a cell-culture result, not a clinical one.

What the human skin trials actually found

After CO2 laser resurfacing (Miller 2006). Patients had circumoral skin resurfaced with a CO2 laser, then were randomized to post-treatment skin care with or without GHK-Cu. Thirteen patients completed. Computer analysis and blinded evaluators found no statistically significant difference between groups for earlier resolution of redness. All patients improved in wrinkles and overall skin appearance, but no difference was found between groups. The patient questionnaire did show a significant difference in post-treatment overall skin quality favoring GHK-Cu (P=.04) [2]. The trial is very small, its objective measures were negative, and its positive finding is a self-assessment.

Venous stasis ulcers (Bishop 1992). In this randomized trial, 86 evaluable patients completed treatment [1]. A 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo for ulcer size, while silver sulfadiazine 1% did statistically reduce ulcer size [1].

Objective measures did not show a GHK-Cu benefit in either trial [1][2]. A 2026 systematic review describes the broader human literature as thin and fragmented: it screened 1,247 records, kept 64, and notes that most randomized trials are small and run on facial cosmetic creams, and that microneedle delivery has not been tested in a registered, adequately powered human randomized trial [7].

Does GHK-Cu grow hair?

We found no randomized human trial that measured hair count, follicle diameter or hair density in people treated with GHK-Cu. Hair claims rest on the peptide's proposed biology and on animal work, not on human outcomes [5][7]. That is an evidence gap, not a finding of no effect.

The 4,000-gene figure

A 2015 review by the researchers who proposed GHK states that GHK is capable of up- and downregulating at least 4,000 human genes, and describes this as essentially resetting DNA to a healthier state [5]. That is a gene-expression observation from laboratory work summarized in a narrative review, not a clinical outcome. A second review by the same researchers describes broader protective actions, including suppression of molecules such as NFkB that are thought to accelerate diseases of aging [11]. Neither review is a randomized trial, and the cosmetic-product benefits they describe come largely from laboratory and company-generated data [5].

Safety, labeling and legal status

No FDA-approved drug is known to contain GHK-Cu [3][4]. GHK-Cu is distinct from copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [4].

Topical products are sold as cosmetics. Under the federal law FDA describes, cosmetic ingredients other than color additives do not need FDA approval before sale, and FDA decides whether a product is a cosmetic or a drug by its intended use: claims to treat disease or to affect the body's structure or function make it a drug [6]. A copper peptide cream sold for appearance sits on the cosmetic side of that line; labeling that claims to restore hair growth or regenerate cells would make it a drug [6].

Compounded non-injectable GHK-Cu. FDA's interim policy places substances nominated for the bulk-substances list into categories. Non-injectable GHK-Cu sits in category 1, the group FDA generally does not intend to act against compounders over, provided the conditions in its guidance are met [12]. Its status has changed: it was removed from category 1 on April 22, 2026 when the nominations were withdrawn, a nominator clarified on May 5, 2026 that only the injectable route had been withdrawn, and FDA added non-injectable GHK-Cu back, with the list updated May 14, 2026 [3][12]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether to include GHK-Cu on the pharmacy bulks list; no vote has happened [3]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [13].

Injectable GHK-Cu is viewed differently. Injectable GHK-Cu appears in the 'nominated but withdrawn' table of FDA's page on bulk substances that may present significant safety risks. FDA's stated concern is that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity from the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [8].

Reported side effects. No adverse-event rate was found in either randomized trial report for the topical copper tripeptide products used [1][2].

What to check on a product

Three things can be read off a product page: whether the label makes disease or hair-growth claims, which would make the product a drug by FDA's definition [6]; whether the route is topical or injectable, a distinction FDA has flagged for the injectable form [8]; and the stated strength, since the only drug-style human trial found tested a 0.4% cream [1].